Definition

Beckwith-Wiedemann syndrome is an overgrowth disorder with:

• Macroglossia
• Abdominal wall defects
• Visceromegaly

It was first described in 1964 by Dr H R Wiedemann, a geneticist from Kiel in Germany.¹ Dr J Bruce Beckwith, a paediatric pathologist working in California, also described it in 1969.² The severity of effect on the child is highly variable, with the majority minimally affected.

Pathogenesis

The underlying cause is unclear. 80% of cases have genotypic abnormalities on the distal portion of chromosome 11p. The reported pattern of inheritance is autosomal dominance with variable expression. There is contiguous gene duplication at band 11p.15.5.³ This is always derived from the patient's father, whereas translocation and inversion are invariably derived from the mother. There appears to be aberrant genomic imprinting resulting from a defective or absent copy of the maternally derived gene - uniparental disomy.

Most sporadic cases lack apparent cytogenetic abnormalities. Only 2% carry inversions, translocations or deletions. 20% of sporadic cases have uniparental disomy.⁴ 50% have loss of methylation.
Most patients with Beckwith-Wiedemann syndrome (BWS) show biallelic expression of IGF2 (insulin-like growth factor 2) in various tissues - see below under Presentation.

Epidemiology

Incidence

Clusters in families in 15% of cases. Most are sporadic.
1 in 15,000 in the USA.⁵
Approximately 1 in 13,700 for rest of Western world. There is no predilection for race or gender.

Recent work has suggested an association between genetic imprinting disorders (such as BWS and Angelman's syndrome) and children conceived with assisted reproduction techniques (ARTs) such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).^6,7 1-3% of births result from these techniques, and the figure is rising. Studies from Britain, France and the USA showed unexpectedly high numbers of BWS cases in children conceived this way.^8,9

Presentation

Increasingly commonly diagnosed at prenatal ultrasound.¹⁰ Suspicious features include:

• Increased abdominal circumference
• Large kidneys
• Large placenta, raised amniotic fluid volume
• Protruding tongue
• Large for gestational age fetus
• Raised alpha-fetoprotein with omphalocele

Symptoms

• Hypoglycaemia
• Poor feeding
• Lethargy
• Problems with breathing, eating and speech, relating to the severity of macroglossia

Signs

• Growth
  • Large for gestational age; the overgrowth in BWS is often the result of increased IGF 2 action in the tissues. Birth weight and length are increased. Hemihypertrophy can be seen, where one part of the body, or usually all or part of one side of the body is enlarged. This often becomes apparent in later childhood.
  • Accelerated growth (on 90th centile or above)
• Abdominal wall defects
  • Omphalocele¹¹ and umbilical hernia
  • Diastasis recti causing a 'pot-belly' appearance
• Visceromegaly
  • Enlarged liver, kidneys, pancreas and spleen are found
• Facial abnormalities
  • Large, prominent eyes
  • Creases in ear lobes and pit behind the upper ear
  • Pinna abnormalities, low-set ears
  • Raised fontanelle, prominent occiput
  • Metopic ridge, prominent on forehead due to early closure of fontanelle
• Others
  • Seizures
  • Cryptorchidism
  • Early bone maturation
  • Naevus flammeus - stork bite mark over eyelids and forehead
  • Renal structural anomalies, nephrocalcinosis

Differential diagnosis

• Fetal overgrowth syndromes, e.g. Simpson-Golabi-Behmel syndrome, Perlman syndrome, Costello syndrome
• Glycogen storage disorders; type 0 or 1
• Hyperinsulinaemia
• Hyperpituitarism
• Hypoglycaemia
• Nesidioblastosis
• Obesity

Investigations

• X-ray long bones
• Blood sugar testing
• X-ray, ultrasound, CT/MRI scan of abdomen
• Chromosome analysis

Associated diseases

There is an increased risk of tumour development in children with BWS:

• The incidence of malignant tumours in reported cases is 5-10%.
• The most common of these is Wilms' nephroblastoma. This occurs in 5-7%. Others are hepatoblastoma and adrenal tumours. Neuroblastomas are less common.
• The risk of cancer is age-dependent with most occurring by age 4 years. 95% have occurred by the age of 8 years.¹²

Management

General measures

Screening for tumours:^8,13

• The child should have alpha-fetoprotein levels (marker for hepatoblastoma) measured every 6 weeks until 3 years old.¹⁴
• Also, abdominal ultrasound scan every 3 months until 8 years old.^15,16

Pharmacological

• Hypoglycaemia should be rigorously avoided and treated, when necessary.
• Diazoxide can be used to inhibit insulin secretion. Paediatric dose of 5-15 mg/kg per day, divided 8-12-hourly.

Surgical

• If the tongue protrudes and interferes with speech and dental development, the child should be considered for reduction surgery before 4 years old.
• Abdominal wall defects will need early neonatal repair. Testes may need bringing down within the scrotum.

Complications

Most can be anticipated and managed:

• Premature delivery
• Monozygotic twinning (usually female and discordant)
• Neonatal hypoglycaemia; uncontrolled hypoglycaemia in infancy is thought to be the major aetiological factor in the reported low IQ in BWS, rather than congenital malformation.

Prognosis

Children who survive infancy do well. There is a 20% infant mortality rate from complications of prematurity, hypoglycaemia and, more rarely, cardiomyopathy.⁹ The older the child becomes, the more normal they appear. Most children have very subtle problems, which do not affect their quality of life.

Document references

1. Wiedemann HR; The EMG-syndrome: exomphalos, macroglossia, gigantism and disturbed carbohydrate metabolism. Z Kinderheilkd. 1969;106(3):171-85.
2. Beckwith J. Macroglossia, omphalocoele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly. Birth Defects, 1969.(5) 188; Original descriptive paper
3. Beckwith-Wiedemann Syndrome, Online Mendelian Inheritance in Man (OMIM)
4. Bestor TH; Imprinting errors and developmental asymmetry. Philos Trans R Soc Lond B Biol Sci. 2003 Aug 29;358(1436):1411-5. [abstract]
5. Ferry RJ; Beckwith-Wiedemann Syndrome. eMedicine, May 2009.
6. Gosden R, Trasler J, Lucifero D, et al; Rare congenital disorders, imprinted genes, and assisted reproductive technology. Lancet. 2003 Jun 7;361(9373):1975-7. [abstract]
7. Klemetti R, Gissler M, Sevon T, et al; Children born after assisted fertilization have an increased rate of major congenital anomalies. Fertil Steril. 2005 Nov;84(5):1300-7. [abstract]
8. Beckwith JB; Children at increased risk for Wilms tumor: monitoring issues. J Pediatr. 1998 Mar;132(3 Pt 1):377-9.
9. Pettenati MJ, Haines JL, Higgins RR, et al; Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet. 1986 Oct;74(2):143-54. [abstract]
10. Williams DH, Gauthier DW, Maizels M; Prenatal diagnosis of Beckwith-Wiedemann syndrome. Prenat Diagn. 2005 Oct;25(10):879-84. [abstract]
11. Grati FR, Turolla L, D'Ajello P, et al; Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome. J Med Genet. 2007 Apr;44(4):257-63. Epub 2007 Jan 26. [abstract]
12. DeBaun MR, Tucker MA; Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998 Mar;132(3 Pt 1):398-400. [abstract]
13. The Wilms Tumour Surveillance Working Group. Surveillance for Wilms Tumour in at-risk individuals - pragmatic recommendations for Best Practice; April 2005
14. Clericuzio CL, Chen E, McNeil DE, et al; Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr. 2003 Aug;143(2):270-2. [abstract]
15. Tan TY, Amor DJ; Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health. 2006 Sep;42(9):486-90. [abstract]
16. McNeil DE, Brown M, Ching A, et al; Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model. Med Pediatr Oncol. 2001 Oct;37(4):349-56. [abstract]

Acknowledgements